How do we make medicines in space? Lynn J. Rothschild explains how biologic medicines can be made on demand.

Are seriously ill patients vulnerable to overestimating the benefits and underestimating the risks of gene editing studies?

Ross Burn presents the story behind his career, including setting up a company on process chemistry and his views on industry 4.0.

Implementing green practices in clinical trials.

Oligonucleotide-based therapeutics present manufacturers with specific processing and characterization challenges.

Pfizer and BioNTech claim their two-dose COVID-19 mRNA vaccine (BNT162b2) is more than 90 percent effective.

Sitting Down With… Will Downie, CEO of Vectura Group, UK, to discuss his career and passion for business.

Novo Nordisk's Stephen Gough explains how pharma can address the cardiovascular risks associated with type 2 diabetes.

We ask medicine makers around the world to tell us how their professional and personal lives have changed over the course of the COVID-19 crisis.

How can we effectively manage the treatment of type 1 diabetes?